Announcements
Sidley Represents ADARx Pharmaceuticals in Its US$200 Million Series C Financing
August 9, 2023
Sidley represented ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing next-generation RNA therapeutics, in its successful close of an oversubscribed US$200 million Series C financing led by Bain Capital and TCGX. The proceeds from the Series C financing will be used to further advance ADARx’s clinical programs, including drug candidates for the treatment of multiple complement-mediated diseases and hereditary angioedema, and to support advancement of a pipeline of innovative mRNA silencing or editing candidates.
The Sidley team was led by James Lu (Emerging Companies and Venture Capital) and Feifei Bian (M&A), and included Jake Funk and Derek W. Kang (M&A).
Contacts
Offices
Capabilities
Suggested News & Insights
Shareholder Engagement in Flux: Recent Developments and Practical ImplicationsFebruary 10, 2026Sidley Represents SanegeneBio in up to US$1.5 Billion Licensing Agreement With GenentechFebruary 10, 2026Understanding Demands on Clients Helps Firms Give Turnkey AdviceFebruary 10, 2026Sidley Advises Ariel Investments in Its First Close of Project LevelFebruary 9, 2026Sidley Represents Lead Arranger in US$1 Billion Financing to Navitas and Rockhopper for First-Ever Development of the Falklands Islands Sea Lion FieldFebruary 9, 2026Sidley Represents Optimas Solutions in the Carve-Out Sale of Its International BusinessFebruary 6, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory